CYCLE-AD (CYcling to Cease or Limit the Effects of Alzheimer's Disease)

Status Recruiting

Clinical Trial Summary

The overall goal of the CYCLE-AD trial is to determine the role of long-term, high intensity exercise in slowing or delaying the onset of cognitive and AD-related brain changes in e4 carriers. Successful translation and demonstration of the effectiveness of a scalable home-based exercise intervention capable of slowing or delaying disease onset will transform AD treatment, improve patient outcomes and quality of life, and reduce health care costs.

Clinical Trial Description

The apolipoprotein E epsilon 4 (APOE e4) allele is the most important genetic risk factor for late onset Alzheimer's disease (AD). A recent review by the World Health Organization highlighted the potential protective role of physical activity and exercise against cognitive decline, all-cause dementia, AD, and vascular dementia in healthy individuals. In an 18-month longitudinal observational study, investigators showed that sedentary e4 carriers experience significant declines in episodic memory and hippocampal volume compared to 4 carriers who engaged in moderate PA. Importantly, among 4 non-carriers, no significant longitudinal changes in cognition and brain imaging were observed whether the non-carriers were sedentary or engaged in moderate PA, suggesting that PA has a specific neuroprotective role in delaying the progression of AD in e4 carriers. Based on the results, a pragmatic, randomized controlled trial with blinded clinical and imaging outcomes is proposed to determine the impact of a home based, high intensity exercise intervention in healthy, cognitively intact e4 carriers between the ages of 65 and 80 years. The CYCLE-AD (CYcling to Cease or Limit the Effects of Alzheimer's Disease) trial will recruit otherwise healthy sedentary carriers randomized to one of two groups (n=75 each): 1) an Indoor Cycling (IC) group that participates in high-intensity interval training (HIIT; 60-90% of heart rate reserve) in their home via the commercially available Peloton® cycling system or 2) a Usual and Customary Care (UCC) group, in which participants engage in their habitual level of PA. Investigators hypothesize that an 18-month high-intensity aerobic exercise regimen will slow AD-related disease progression in sedentary elders at genetic risk for AD. Participants in the intervention group will engage in exercise 3x/week (minimum 90 minutes/week) for 18 months. Primary outcome measures, obtained at study entry and at 18 months, will include comprehensive cognitive testing and brain MR imaging to assess disease progression and a comprehensive PA/fitness assessment to measure the degree of change in physical fitness due to high intensity aerobic exercise. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04748861
Study type	Interventional
Source	The Cleveland Clinic
Contact	Stephen Rao, PhD
Phone	216-444-1025
Email	raos2@ccf.org
Status	Recruiting
Phase	N/A
Start date	October 20, 2021
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05835297` - Effect of Specifically Developed Exercise Intervention on Falls Among Older Adults in Nursing Homes	N/A
Recruiting	`NCT05392270` - Influence of Cognition on Activity and Participation in People With Stroke	N/A
Completed	`NCT04906525` - Resistance Training Effects on Gut Microbiome and Cardiometabolic Outcomes	N/A
Recruiting	`NCT04821076` - Influence of Low Energy Availability on Skeletal Muscle and Cardiovascular Health	N/A
Completed	`NCT03807518` - Pre- and Post-Operative Exercise Program in Upper Gastrointestinal Cancers	N/A
Recruiting	`NCT02533947` - Cognition in Allogeneic Stem Cell Transplanted Patients and Sports	N/A
Completed	`NCT04808869` - Effectiveness of Blood Flow Restriction During Aerobic Cycling	N/A
Completed	`NCT04112758` - Exercise Intervention on Conflict Monitoring in Children With Attention-deficit Hyperactivity Disorder	N/A
Completed	`NCT01523353` - Prehabilitation in Liver Surgery	Phase 1
Completed	`NCT06096467` - The Impact of Exercise Intervention on Physical Function Falls, and Physical Restraint for Long-term Care Residents	N/A
Completed	`NCT05260567` - Telehealth Exercise Training in Peripheral Arterial Disease - TEXT-PAD	N/A
Completed	`NCT05843591` - Exercise Interventions on Problematic Mobile Phone Use: a Multi-arm Randomized Controlled Trial
Completed	`NCT04944251` - Regular Exercise Improves Physical Capacity and Promotes Neurotrophins in Patients With Multiple Sclerosis	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

CYCLE-AD (CYcling to Cease or Limit the Effects of Alzheimer's Disease) — CYCLE-AD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms